Imidazobenzazepine CGRP receptor antagonists

A compound of formula (II):

• wherein:
• A is NR5 or C(R5)2;
• Z is selected from:
• and when A is NR5, Z is additionally selected from:
• R1A and R1B are independently selected from:
• 1) H, C1-C6 alkyl, C3-6 cycloalkyl and heterocycle, wherein said alkyl, cycloalkyl and heterocycle is optionally substituted with one or more substituents each independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) aryl, unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from R5,
• d) heteroaryl, unsubstituted or substituted with 1-5 substituents each independently selected from R5,
• e) heterocycle, unsubstituted or substituted with 1-5 substituents each independently selected from R5,
• f) (F)pC1-3 alkyl,
• g) halogen,
• h) OR5,
• i) O(CH2)sOR5,
• j) CO2R5,
• k) CN,
• l) NR10R11, and
• m) O(CO)R5;
• and
• 2) aryl or heteroaryl, wherein said aryl or heteroaryl is optionally substituted with one or more substituents independently selected from:
• a) C1-6 alkyl,
• b) C3-6 cycloalkyl,
• c) (F)pC1-3 alkyl,
• d) halogen,
• e) OR5,
• f) CO2R5,
• g) (CO)NR10R11,
• h) SO2NR10R11,
• i) N(R10) SO2R11,
• j) S(O)mR5,
• k) CN,
• l) NR10R11, and
• m) O(CO)R4;
• R4 is hydrogen, halo, C1-6alkyl, or C2-6 alkenyl;
• R5 is selected from:
• H, C1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, wherein said alkyl, cycloalkyl, aryl or heteroaryl moiety is optionally substituted with halogen, hydroxy or C1-C6 alkoxy;
• R10 and R11 are independently selected from:
• H, C1-6 alkyl, C3-6 cycloalkyl, aryl, heteroaryl and benzyl, wherein said alkyl, cycloalkyl, aryl or heteroaryl moiety is optionally substituted with halogen, hydroxy or C1-C6 alkoxy, provided that when R10 and R11 are bonded to the same nitrogen atom, then R10 and R11 and the nitrogen to which they are both attached form a ring selected from:
• azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl, which ring is unsubstituted or substituted with 1-5 substituents each independently selected from R5;
• p is 0 to 2q+1, for a substituent with q carbons
• m is 0 to 2;
• s is 1 to 3
• or a pharmaceutically acceptable salt thereof, or individual stereoisomer thereof.